FocalTherics Q2 revenue up 39% to $13.2M; net loss widens; $40M offering

EDAP TMS SA

Revenue $13.2M, +39% YoY; U.S. procedure volume +47%; 13 Focal One systems sold vs 9.
Gross margin 55.6% vs 51.1%; operating loss $8.0M vs $6.6M; net loss $14.4M ($0.38/sh) vs $6.4M.
ESWL and Distribution reclassified as discontinued operations; HIFU now only continuing ops; cash $21.5M.
FY2026 revenue guidance reaffirmed $50-54M (34-45% growth); $40M public offering expected to close Aug 14.
Launched first commercial Focal One Endometriosis program in Europe; installed base 184 (96 U.S.).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.